Reports

Industry Research Reports

description

Part 1

description

Part 2

description

Part 3

description

Part 5

Home > Reports > Medical Care > Global Pulmonary Arterial Hypertension (PAH) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Global Pulmonary Arterial Hypertension (PAH) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Global Pulmonary Arterial Hypertension (PAH) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Industry: Medical Care

Published: 2023-06-02

Pages: 86 Pages

Report ld: 1279829

申请样本

Request Sample

定制报告

Pre-Order Enquiry

申请样本

Request Sample

定制报告

Pre-Order Enquiry

  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
Pulmonary Arterial Hypertension (PAH) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pulmonary Arterial Hypertension (PAH) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.

North America, Europe and Asia Pacific are the key regions for Pulmonary Arterial Hypertension (PAH) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2029. 
Globally, Pulmonary Arterial Hypertension (PAH) key companies include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. Actelion, Gilead Sciences, United Therapeutics are top 3 players and held % share in total in 2022.

Pulmonary Arterial Hypertension (PAH) can be divided into Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA and PDE-5, etc. Prostacyclin and Prostacyclin Analogs is the mainstream product in the market, accounting for % share globally in 2022.

Pulmonary Arterial Hypertension (PAH) is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Pulmonary Arterial Hypertension (PAH) industry development. In 2022, global % share of Pulmonary Arterial Hypertension (PAH) went into Hospital filed. 
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pulmonary Arterial Hypertension (PAH) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Companies, Type, Application and Regions Listed in the Report:
By Company
    Actelion
    Gilead Sciences
    United Therapeutics
    GlaxoSmithKline
    Pfizer
    Bayer
    Arena

Segment by Type
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5

Segment by Application
    Hospital
    Clinic

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        
    Latin America
        Mexico
        Brazil
        
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Pulmonary Arterial Hypertension (PAH) market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Pulmonary Arterial Hypertension (PAH) introduction, etc. Pulmonary Arterial Hypertension (PAH) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Pulmonary Arterial Hypertension (PAH) market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.
  
 1 Market Overview of Pulmonary Arterial Hypertension (PAH)
    1.1 Pulmonary Arterial Hypertension (PAH) Market Overview
        1.1.1 Pulmonary Arterial Hypertension (PAH) Product Scope
        1.1.2 Pulmonary Arterial Hypertension (PAH) Market Status and Outlook
    1.2 Global Pulmonary Arterial Hypertension (PAH) Market Size Overview by Region 2018 VS 2022 VS 2029
    1.3 Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2029)
    1.4 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2018-2023)
    1.5 Global Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Region (2024-2029)
    1.6 Key Regions, Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
        1.6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
        1.6.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
        1.6.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
        1.6.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)
        1.6.5 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029)

 2 Pulmonary Arterial Hypertension (PAH) Market by Type
    2.1 Introduction
        2.1.1 Prostacyclin and Prostacyclin Analogs
        2.1.2 SGC Stimulators
        2.1.3 ERA
        2.1.4 PDE-5
    2.2 Global Pulmonary Arterial Hypertension (PAH) Market Size by Type: 2018 VS 2022 VS 2029
        2.2.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2018-2023)
        2.2.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2024-2029)
    2.3 Key Regions Market Size by Type
        2.3.1 North America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
        2.3.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
        2.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
        2.3.4 Latin America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)
        2.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Type (2018-2029)

 3 Pulmonary Arterial Hypertension (PAH) Market Overview by Application
    3.1 Introduction
        3.1.1 Hospital
        3.1.2 Clinic
    3.2 Global Pulmonary Arterial Hypertension (PAH) Market Size by Application: 2018 VS 2022 VS 2029
        3.2.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2018-2023)
        3.2.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2024-2029)
    3.3 Key Regions Market Size by Application
        3.3.1 North America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
        3.3.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
        3.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
        3.3.4 Latin America Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)
        3.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Breakdown by Application (2018-2029)

 4 Pulmonary Arterial Hypertension (PAH) Competition Analysis by Players
    4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Players (2018-2023)
    4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2022)
    4.3 Date of Key Players Enter into Pulmonary Arterial Hypertension (PAH) Market
    4.4 Global Top Players Pulmonary Arterial Hypertension (PAH) Headquarters and Area Served
    4.5 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
    4.6 Competitive Status
        4.6.1 Pulmonary Arterial Hypertension (PAH) Market Concentration Rate
        4.6.2 Mergers & Acquisitions, Expansion Plans

 5 Company (Top Players) Profiles
    5.1 Actelion
        5.1.1 Actelion Profile
        5.1.2 Actelion Main Business
        5.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.1.4 Actelion Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.1.5 Actelion Recent Developments
    5.2 Gilead Sciences
        5.2.1 Gilead Sciences Profile
        5.2.2 Gilead Sciences Main Business
        5.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.2.5 Gilead Sciences Recent Developments
    5.3 United Therapeutics
        5.3.1 United Therapeutics Profile
        5.3.2 United Therapeutics Main Business
        5.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.3.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.3.5 GlaxoSmithKline Recent Developments
    5.4 GlaxoSmithKline
        5.4.1 GlaxoSmithKline Profile
        5.4.2 GlaxoSmithKline Main Business
        5.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.4.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.4.5 GlaxoSmithKline Recent Developments
    5.5 Pfizer
        5.5.1 Pfizer Profile
        5.5.2 Pfizer Main Business
        5.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.5.4 Pfizer Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.5.5 Pfizer Recent Developments
    5.6 Bayer
        5.6.1 Bayer Profile
        5.6.2 Bayer Main Business
        5.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.6.4 Bayer Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.6.5 Bayer Recent Developments
    5.7 Arena
        5.7.1 Arena Profile
        5.7.2 Arena Main Business
        5.7.3 Arena Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
        5.7.4 Arena Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) & (2018-2023)
        5.7.5 Arena Recent Developments

 6 North America
    6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
    6.2 U.S.
    6.3 Canada

 7 Europe
    7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
    7.2 Germany
    7.3 France
    7.4 U.K.
    7.5 Italy
    7.6 Russia
    7.7 Nordic Countries
    7.8 Rest of Europe

 8 Asia-Pacific
    8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2029)
    8.2 China
    8.3 Japan
    8.4 South Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australia
    8.8 Rest of Asia-Pacific

 9 Latin America
    9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
    9.2 Mexico
    9.3 Brazil
    9.4 Rest of Latin America

 10 Middle East & Africa
    10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2029)
    10.2 Turkey
    10.3 Saudi Arabia
    10.4 UAE
    10.5 Rest of Middle East & Africa

 11 Pulmonary Arterial Hypertension (PAH) Market Dynamics
    11.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
    11.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
    11.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
    11.4 Pulmonary Arterial Hypertension (PAH) Market Restraints

 12 Research Finding /Conclusion

 13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List
 
List of Tables
    Table 1. Global Market Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Region (2018-2023)
    Table 4. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2023)
    Table 9. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2024-2029)
    Table 11. North America Pulmonary Arterial Hypertension (PAH) Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Pulmonary Arterial Hypertension (PAH) Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Pulmonary Arterial Hypertension (PAH) Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Pulmonary Arterial Hypertension (PAH) Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Pulmonary Arterial Hypertension (PAH) Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Pulmonary Arterial Hypertension (PAH) Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2023)
    Table 24. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2024-2029)
    Table 26. North America Pulmonary Arterial Hypertension (PAH) Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Pulmonary Arterial Hypertension (PAH) Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Pulmonary Arterial Hypertension (PAH) Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Pulmonary Arterial Hypertension (PAH) Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Pulmonary Arterial Hypertension (PAH) Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Pulmonary Arterial Hypertension (PAH) Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Pulmonary Arterial Hypertension (PAH) Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2022)
    Table 39. Date of Key Players Enter into Pulmonary Arterial Hypertension (PAH) Market
    Table 40. Global Pulmonary Arterial Hypertension (PAH) Key Players Headquarters and Area Served
    Table 41. Pulmonary Arterial Hypertension (PAH) Product Solution and Service
    Table 42. Global Pulmonary Arterial Hypertension (PAH) Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Actelion Basic Information List
    Table 45. Actelion Description and Business Overview
    Table 46. Actelion Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of Actelion (2018-2023)
    Table 48. Actelion Recent Developments
    Table 49. Gilead Sciences Basic Information List
    Table 50. Gilead Sciences Description and Business Overview
    Table 51. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of Gilead Sciences (2018-2023)
    Table 53. Gilead Sciences Recent Developments
    Table 54. United Therapeutics Basic Information List
    Table 55. United Therapeutics Description and Business Overview
    Table 56. United Therapeutics Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of United Therapeutics (2018-2023)
    Table 58. United Therapeutics Recent Developments
    Table 59. GlaxoSmithKline Basic Information List
    Table 60. GlaxoSmithKline Description and Business Overview
    Table 61. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of GlaxoSmithKline (2018-2023)
    Table 63. GlaxoSmithKline Recent Developments
    Table 64. Pfizer Basic Information List
    Table 65. Pfizer Description and Business Overview
    Table 66. Pfizer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 67. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of Pfizer (2018-2023)
    Table 68. Pfizer Recent Developments
    Table 69. Bayer Basic Information List
    Table 70. Bayer Description and Business Overview
    Table 71. Bayer Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 72. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of Bayer (2018-2023)
    Table 73. Bayer Recent Developments
    Table 74. Arena Basic Information List
    Table 75. Arena Description and Business Overview
    Table 76. Arena Pulmonary Arterial Hypertension (PAH) Products, Services and Solutions
    Table 77. Revenue (US$ Million) in Pulmonary Arterial Hypertension (PAH) Business of Arena (2018-2023)
    Table 78. Arena Recent Developments
    Table 79. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
    Table 80. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2029) & (US$ Million)
    Table 81. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
    Table 82. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2029) & (US$ Million)
    Table 83. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 84. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2023) & (US$ Million)
    Table 85. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2024-2029) & (US$ Million)
    Table 86. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2018-2023)
    Table 87. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2024-2029)
    Table 88. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 89. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
    Table 90. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2029) & (US$ Million)
    Table 91. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 92. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
    Table 93. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2029) & (US$ Million)
    Table 94. Pulmonary Arterial Hypertension (PAH) Market Trends
    Table 95. Pulmonary Arterial Hypertension (PAH) Market Drivers
    Table 96. Pulmonary Arterial Hypertension (PAH) Market Challenges
    Table 97. Pulmonary Arterial Hypertension (PAH) Market Restraints
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions: 2022 VS 2029
    Figure 4. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of Prostacyclin and Prostacyclin Analogs
    Figure 11. Global Prostacyclin and Prostacyclin Analogs Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of SGC Stimulators
    Figure 13. Global SGC Stimulators Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Product Picture of ERA
    Figure 15. Global ERA Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 16. Product Picture of PDE-5
    Figure 17. Global PDE-5 Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 18. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Type:  2022 & 2029
    Figure 19. North America Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2029)
    Figure 20. Europe Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2029)
    Figure 21. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2029)
    Figure 22. Latin America Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2029)
    Figure 23. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2029)
    Figure 24. Hospital Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 25. Clinic Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 26. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Application: 2022 & 2029
    Figure 27. North America Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2029)
    Figure 28. Europe Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2029)
    Figure 29. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2029)
    Figure 30. Latin America Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2029)
    Figure 31. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2029)
    Figure 32. Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 33. Global Top 5 and Top 10 Players Pulmonary Arterial Hypertension (PAH) Market Share in 2022
    Figure 34. North America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2029)
    Figure 35. U.S. Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 36. Canada Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 37. Germany Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 38. France Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 39. U.K. Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 40. Italy Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 41. Russia Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 42. Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 43. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2018-2029)
    Figure 44. China Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 45. Japan Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 46. South Korea Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 47. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 48. India Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 49. Australia Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 50. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2029)
    Figure 51. Mexico Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 52. Brazil Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 53. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2029)
    Figure 54. Turkey Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 55. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 56. UAE Pulmonary Arterial Hypertension (PAH) Market Size (2018-2029) & (US$ Million)
    Figure 57. Bottom-up and Top-down Approaches for This Report

  
Pulmonary Arterial Hypertension (PAH) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pulmonary Arterial Hypertension (PAH) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.

North America, Europe and Asia Pacific are the key regions for Pulmonary Arterial Hypertension (PAH) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2029. 
 
Globally, Pulmonary Arterial Hypertension (PAH) key companies include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. Actelion, Gilead Sciences, United Therapeutics are top 3 players and held % share in total in 2022.

Pulmonary Arterial Hypertension (PAH) can be divided into Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA and PDE-5, etc. Prostacyclin and Prostacyclin Analogs is the mainstream product in the market, accounting for % share globally in 2022.

Pulmonary Arterial Hypertension (PAH) is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Pulmonary Arterial Hypertension (PAH) industry development. In 2022, global % share of Pulmonary Arterial Hypertension (PAH) went into Hospital filed. 
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pulmonary Arterial Hypertension (PAH) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Companies, Type, Application and Regions Listed in the Report:
By Company
    Actelion
    Gilead Sciences
    United Therapeutics
    GlaxoSmithKline
    Pfizer
    Bayer
    Arena

Segment by Type
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5

Segment by Application
    Hospital
    Clinic

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        
    Latin America
        Mexico
        Brazil
        
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Pulmonary Arterial Hypertension (PAH) market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Pulmonary Arterial Hypertension (PAH) introduction, etc. Pulmonary Arterial Hypertension (PAH) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Pulmonary Arterial Hypertension (PAH) market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.
 
    
 
Global Pulmonary Arterial Hypertension (PAH) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application  
 
Industry: Medical Care
 
Published: 2023-06-02
 
Pages: 86 Pages
 
Report ld: 1279829
 
申请样本 

                Request Sample
              
 
定制报告 

                Pre-Order Enquiry
              
 

          CHOOSE LICENSE TYPE
        
 
 提示
 
USD 3350.00
 
 提示
 
USD 5025.00
 
 提示
 
USD 6700.00
 
 
/uploads/payment/payIcon/masterCard-01.svg/uploads/payment/payIcon/american-express-01.svg/uploads/payment/payIcon/visa-01.svg/uploads/payment/payIcon/diners-club-01.svg/uploads/payment/payIcon/discover-4-01.svg/uploads/payment/payIcon/jcb-01.svg
 
加入购物车 
 Add to Cart 
 
立即购买 
 Buy Now
 
A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.
  
 

      WHAT QYRESEARCH OFFER?
    
 
Competition 
Competition
 
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis 
Industry Analysis
 
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size 
Market Size
 
Capacity, production, sales, revenue, price, cost etc.
Customized Information 
Customized Information
 
We can offer customized survey and information to meet ourclient's need.
 

      INTEREST IN THIS REPORT?
 
 
Get A Free Sample >>
 

        WHY QYR?
      
 
  • Fastest report delivery service 
    Fastest report delivery service
  • More than 17 years of vast experience 
    More than 17 years of vast experience
  • Operation for 24 * 7 & 365 days 
    Operation for 24 * 7 & 365 days
  • In-depth and comprehensive analysis 
    In-depth and comprehensive analysis
  • Professional and timely after-sales service 
    Professional and timely after-sales service
  • Owns large database 
    Owns large database
 
 
A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.
  
 

      WHAT QYRESEARCH OFFER?
    
 
Competition 
Competition
 
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis 
Industry Analysis
 
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size 
Market Size
 
Capacity, production, sales, revenue, price, cost etc.
Customized Information 
Customized Information
 
We can offer customized survey and information to meet ourclient's need.
 

      INTEREST IN THIS REPORT?
 
 
Get A Free Sample >>
 

        WHY QYR?
      
 
  • Fastest report delivery service 
    Fastest report delivery service
  • More than 17 years of vast experience 
    More than 17 years of vast experience
  • Operation for 24 * 7 & 365 days 
    Operation for 24 * 7 & 365 days
  • In-depth and comprehensive analysis 
    In-depth and comprehensive analysis
  • Professional and timely after-sales service 
    Professional and timely after-sales service
  • Owns large database 
    Owns large database
 
 
biaoTi 
WORLD WIDE OFFICE
  
 
 
 
 
 
 
 
加入购物车 
Add to Cart
 
立即购买 
 Buy Now